COMMUNIQUÉS West-GlobeNewswire

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study
12/01/2026
Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation [...]
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
12/01/2026
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most [...]
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that [...]
Acentra Health Honored as One of Modern Healthcare’s 2025 Best in Business
12/01/2026
The company earned recognition in the highly competitive Healthcare IT category for its configurable, modular solutions MCLEAN, Va., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions [...]
Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures
12/01/2026
PRESS RELEASE, 01/12/2026, 10:00 EST Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures Itasca, IL, US, 12 January 2026 – Biocartis announced today that it has entered into a research [...]
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
12/01/2026
Company to present at the 44th Annual JP Morgan Healthcare Conference FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced [...]
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
12/01/2026
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and [...]
Teladoc Health Launches Enhanced 24/7 Care Service
12/01/2026
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: [...]
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
12/01/2026
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan [...]
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
12/01/2026
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or [...]
Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance
12/01/2026
Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical [...]
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies Expected 2026 oncology [...]
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
12/01/2026
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 [...]
Pharvaris Outlines 2026 Strategic Priorities
12/01/2026
Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; [...]
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
12/01/2026
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator
12/01/2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company implementing a Solana-based digital asset treasury strategy, today announced the [...]
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
12/01/2026
REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Skye Provides 2026 Corporate Outlook
12/01/2026
CBeyond TM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety profile. [...]
Lyra Therapeutics Provides Corporate Update
12/01/2026
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the [...]

Pages